{
    "clinical_study": {
        "@rank": "149883", 
        "brief_summary": {
            "textblock": "Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus\n      isolation. Examine the ability of thymopentin to stimulate the immune system and alter the\n      clinical findings in patients infected with HIV who do not yet have AIDS."
        }, 
        "brief_title": "The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Aerosolized pentamidine.\n\n        Patients must have the following:\n\n          -  Seropositive for HIV-1 (ELISA assay) confirmed by Western blot.\n\n          -  HIV-1 p24 antigen must be detected in supernatant fluids from co-cultures of\n             patients' peripheral blood monocytes (PBMC) on two separate occasions.\n\n          -  Voluntarily sign consent.\n\n          -  Patients with HIV \"wasting syndrome\" are allowed.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  Aerosolized pentamidine.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following are excluded:\n\n          -  AIDS as defined by the CDC.\n\n          -  Significant hepatic disease.\n\n          -  Thrombocytopenia.\n\n          -  Hypersensitivity to thymopentin.\n\n          -  Hemophilia A or B or other hematologic disorders requiring current or previous\n             administration of blood products.\n\n          -  Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within\n             30 days prior to study entry.\n\n        Patients with the following are excluded:\n\n          -  AIDS as defined by the CDC.\n\n          -  Significant hepatic disease.\n\n          -  Thrombocytopenia.\n\n          -  Hypersensitivity to thymopentin.\n\n          -  Hemophilia A or B or other hematologic disorders requiring current or previous\n             administration of blood products.\n\n          -  Abnormal chest x-ray (indicative of active disease (opportunistic infection)) within\n             30 days prior to study entry.\n\n        Prior Medication:\n\n        Excluded within 30 days of study entry:\n\n          -  Immunomodulatory or experimental therapy.\n\n          -  Excluded within 90 days of study entry:\n\n          -  Zidovudine (AZT).\n\n        Intravenous drug abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002289", 
            "org_study_id": "015C", 
            "secondary_id": "H87-047 modified"
        }, 
        "intervention": {
            "intervention_name": "Thymopentin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Thymopentin"
        }, 
        "keyword": [
            "Semen", 
            "Thymopentin", 
            "Leukocytes, Mononuclear", 
            "HIV Seropositivity", 
            "AIDS-Related Complex"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Annandale", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "088010999"
                }, 
                "name": "Immunobiology Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002289"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Immunobiology Research Institute", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1989"
    }, 
    "geocoordinates": {
        "Immunobiology Research Institute": "40.641 -74.881"
    }
}